Published in J Diabetes Res on April 28, 2015
Sleep Optimization and Diabetes Control: A Review of the Literature. Diabetes Ther (2015) 0.75
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 8.70
Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia (2007) 4.41
beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab (2004) 2.91
Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: possible contributing factors. Neuroimage (2008) 2.86
Insulin-associated weight gain in diabetes--causes, effects and coping strategies. Diabetes Obes Metab (2007) 2.24
Deficits of mesolimbic dopamine neurotransmission in rat dietary obesity. Neuroscience (2009) 2.09
Evidence for defective mesolimbic dopamine exocytosis in obesity-prone rats. FASEB J (2008) 1.99
Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats. J Clin Invest (2006) 1.94
Exposure to elevated levels of dietary fat attenuates psychostimulant reward and mesolimbic dopamine turnover in the rat. Behav Neurosci (2008) 1.90
Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care (2014) 1.86
Variability of insulin absorption and insulin action. Diabetes Technol Ther (2002) 1.83
Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care (2010) 1.65
Neuronal regulation of homeostasis by nutrient sensing. Nat Med (2010) 1.61
Insulin pharmacokinetics. Diabetes Care (1984) 1.60
Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care (2000) 1.55
The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev (2007) 1.55
Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail (2008) 1.48
Hypothalamic responses to long-chain fatty acids are nutritionally regulated. J Biol Chem (2004) 1.44
Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats. Diabetol Metab Syndr (2014) 1.43
Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology (2000) 1.27
Sensing the fuels: glucose and lipid signaling in the CNS controlling energy homeostasis. Cell Mol Life Sci (2010) 1.27
Reduced accumbens dopamine in Sprague-Dawley rats prone to overeating a fat-rich diet. Physiol Behav (2010) 1.22
Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opin Pharmacother (2010) 1.16
Decreased vesicular somatodendritic dopamine stores in leptin-deficient mice. J Neurosci (2007) 1.15
Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. Neuroendocrinology (1999) 1.15
Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab (2011) 1.10
Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin (2011) 1.09
Review article: Thiazolidinediones and heart failure. Diab Vasc Dis Res (2009) 1.08
Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology (1998) 1.03
Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance. Neuroreport (1997) 0.96
Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol (1993) 0.95
Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. PLoS One (2009) 0.93
Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors. Dan Med Bull (1991) 0.91
Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects. J Am Heart Assoc (2012) 0.90
Combined thiazolidinedione-insulin therapy: should we be concerned about safety? Drug Saf (2004) 0.88
Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters. Neuroreport (1999) 0.88
Long-term, intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin resistance: a model for weight gain with intensive insulin therapy. Am J Physiol Endocrinol Metab (2012) 0.87
Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab (2010) 0.86
Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. Neuroendocrinology (1999) 0.86
Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab (2006) 0.85
Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract (2012) 0.83
Chronic infusion of norepinephrine into the VMH of normal rats induces the obese glucose-intolerant state. Am J Physiol Regul Integr Comp Physiol (2000) 0.82
Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Pharmacotherapy (2005) 0.82
Gut-brain signalling: how lipids can trigger the gut. Diabetes Metab Res Rev (2011) 0.81
Circadian insights into dopamine mechanisms. Neuroscience (2014) 0.80